medigraphic.com
ISSN 1527-3172 (Digital)

2018, Número 4

<< Anterior Siguiente >>

MEDICC Review 2018; 20 (4)


Rising cancer drug prices: What can low-and middle-income countries do?

Blanco-García E, Ledón-Naranjo N, Lage-Dávila A

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 35-39
Archivo PDF: 111.29 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86.

  2. Union for International Cancer Control. The Economics of Cancer Prevention and Control. Data Digest [Internet]. Geneva: Union for International Cancer Control; 2014 [cited 2018 Oct 5]. 8 p. Available from: http://issuu.com/ uicc.org/docs/wcls2014_economics_of_can cer_fi nal?e=0

  3. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun;14(6):381–90.

  4. Gross A. The global economic cost of cancer: improving outcomes and cost by reducing international barriers to care. Loy U Chi Int’l L Rev [Internet]. 2015 [cited 2018 Apr 10];12(2):231– 47. Available from: http://lawecommons.luc.edu/ lucilr/vol12/iss2/7

  5. United Nations [Internet]. New York: United Nations; 2003. Commentary on the Norms on the Responsibilities of Transnational Corporations and Other Business Enterprises with Regard to Human Rights, U.N. Doc. E/CN.4/ Sub.2/2003/38/Rev.2; 2003 [cited 2018 Apr 10]. Available from: http://hrlibrary.umn.edu/bu siness/commentary-Aug2003.html

  6. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, effi cacy, and costs. JAMA Oncol. 2015 Jul;1(4):539–40.

  7. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me too mentality that stifl es innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1225–36.

  8. Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016:2(9):1238–40.

  9. Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, et al. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefi t? Ann Oncol. 2017:28(1):157–62.

  10. Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justifi ed? A critical analysis. Cancer. 2015 Oct 1;121(19):3372–9.

  11. United Nations Department of Economic and Social Affairs Population Division. World Population Ageing Report [Internet]. New York: United Nations; 2015 [cited 2018 Apr 10]. 149 p. Available from: https://www.un.org/en/develop ment/desa/population/publications/pdf/ageing/ WPA2015_Report.pdf

  12. Goldstein DA, Clark J, Tu Y, Zhang Y, Fang F, Goldstein RM, et al, editors. Global differences in cancer drug prices: A comparative analysis. J Clin Oncol [Internet]. 2016 [cited 2018 Feb 10];34(Suppl 18). Available from: http://asco pubs.org/doi/abs/10.1200/JCO.2016.34.18 _suppl.LBA6500#

  13. Heymann J, Cassola A, Raub A, Mishra L. Constitutional rights to health, public health and medical care: the status of health protections in 191 countries. Glob Public Health. 2013 Jul;8(6):639–53.

  14. Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2329– 34.

  15. Mazzucato M. The Entrepreneurial State – Debunking Public vs. Private Sector Myths New York: Anthem Press; 2013 Jun 10. 266 p. ISBN 978-0-857282-52-1.

  16. Jacobs M, Mazzucato M. Rethinking Capitalism: Economics and Policy for Sustainable and Inclusive Growth. New Jersey: Wiley-Blackwell; 2016 Jul. ISBN: 978-1-119-12095-7.

  17. IRI - Economics of Industrial Research and Innovation [Internet]. Seville: IRI; c2018. Data World 2500. R&D ranking of the world top 2500 companies; 2017 [cited 2018 Apr 10]. Available from: http://iri .jrc.ec.europa.eu/scoreboard17.html#close

  18. Shah S, Silva MA, Malloy MJ. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice? Nat Biotechnol. 2016 Jul 12;34(7):716–9.

  19. Finch AC, Himes JL, Hollywood M, Pérez M, Reiss W, Sedlak L, et al. Antitrust plays whacka- mole as exclusion of competition by drug monopolists pops up again: Gaming the –REMS–. NYSBA NY Litigator [Internet]. 2016 Fall [cited 2018 Apr 10];21(2):9–18. Available from: http://www.nysba.org/Sections/Antitrust_Law/ Events/2016/REMS_-_Nov_3/NY_Litigator _Article.html

  20. Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med. 2015 Apr;175(4):635–7.

  21. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.

  22. Eichler HG, Baird LG, Barker R, Bloechl-Daum B, Børlum-Kristensen F, Brown J, et al. From adaptive licensing to adaptive pathways: delivering a fl exible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015 Mar;97(3):234–46.

  23. Brawley L. With 20 agents, 803 trials, and 166,736 patient slots, is Pharma investing too heavily in PD-1 drug development? Cancer Lett [Internet]. 2016 Oct 7 [cited 2018 Apr 10];42(37):2–18. Available at: https://cancer letter.com/articles/20161007_1/

  24. World Health Organization [Internet]. Geneva: World Health Organization; c2018. Publications. Essential medicines and health products. WHO Model Lists of Essential Medicines. The 2017 Expert Committee on the Selection and Use of Essential Medicines; 2017 Aug [cited 2018 Apr 10]. Available from: http://www.who.int/medi cines/publications/essentialmedicines/en/

  25. Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, et al. Cancer drugs fund requires further reform. BMJ. 2016 Sep 27;354: i5090.

  26. Sullivan T. Vermont: First State to Pass Pharmaceutical Cost Transparency Bill. Policy and Medicine [Internet]. [place unknown]: Policy &Medicine; 2018 [cited 2018 Apr 10]; [about 3 screens]. Available from: https://www.policymed.com/2016/05/vermont-first -state-to-pass-bill-on-pharmaceutical-cost-trans parency.html

  27. World Trade Organization [Internet]. Geneva: World Trade Organization; c2018. Declaration on the TRIPS agreement and public health; 2001 Nov 20 [cited 2018 Apr 10]; [about 2 screens]. Available from: https://www.wto.org/ english/thewto_e/minist_e/min01_e/mindecl _trips_e.htm

  28. t’Hoen EF, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of fl exibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001– 2016. Bull World Health Organ. 2018 Mar 1;96(3):185–93.

  29. World Health Organization [Internet]. Geneva: World Health Organization; c2018. Public health, innovation, intellectual property and trade. United Nations Secretary-General’s High-Level Panel on Access to Medicines; 2016 Sep [cited 2018 Apr 10]. Available from: http://www.who.int/phi/implementation/ip_trade/high-level-panel-access-med/en/




2020     |     www.medigraphic.com